384 related articles for article (PubMed ID: 38547865)
21. Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes.
Ting NL; Lau HC; Yu J
Gut; 2022 Jul; 71(7):1412-1425. PubMed ID: 35277453
[TBL] [Abstract][Full Text] [Related]
22. The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy.
Gopalakrishnan V; Helmink BA; Spencer CN; Reuben A; Wargo JA
Cancer Cell; 2018 Apr; 33(4):570-580. PubMed ID: 29634945
[TBL] [Abstract][Full Text] [Related]
23. [Association between Immunotherapy with Immune Checkpoint Inhibitors(Anti-PD-1 Antibodies)and Intestinal Microbiota].
Ozaki Y; Suzuki Y; Nishiyama K; Suzutani T; Suzuki H
Gan To Kagaku Ryoho; 2021 Sep; 48(9):1096-1099. PubMed ID: 34521783
[TBL] [Abstract][Full Text] [Related]
24. Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
Matson V; Chervin CS; Gajewski TF
Gastroenterology; 2021 Jan; 160(2):600-613. PubMed ID: 33253684
[TBL] [Abstract][Full Text] [Related]
25. Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer.
Kang YB; Cai Y
World J Gastroenterol; 2021 Aug; 27(32):5362-5375. PubMed ID: 34539138
[TBL] [Abstract][Full Text] [Related]
26. Manipulating the gut and tumor microbiota for immune checkpoint inhibitor therapy: from dream to reality.
Guillot N; Roméo B; Manesh SS; Milano G; Brest P; Zitvogel L; Hofman P; Mograbi B
Trends Mol Med; 2023 Nov; 29(11):897-911. PubMed ID: 37704493
[TBL] [Abstract][Full Text] [Related]
27. Gut Microbiota and Immune Checkpoint Inhibitors-Based Immunotherapy.
Tian M; Zhang S; Tseng Y; Shen X; Dong L; Xue R
Anticancer Agents Med Chem; 2022; 22(7):1244-1256. PubMed ID: 34229597
[TBL] [Abstract][Full Text] [Related]
28. Microbiome-based interventions: therapeutic strategies in cancer immunotherapy.
Soto Chervin C; Gajewski TF
Immunooncol Technol; 2020 Dec; 8():12-20. PubMed ID: 35757563
[TBL] [Abstract][Full Text] [Related]
29. Revealing the therapeutic properties of gut microbiota: transforming cancer immunotherapy from basic to clinical approaches.
Hazra R; Chattopadhyay S; Mallick A; Gayen S; Roy S
Med Oncol; 2024 Jun; 41(7):175. PubMed ID: 38874788
[TBL] [Abstract][Full Text] [Related]
30. Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapy.
Huang J; Jiang Z; Wang Y; Fan X; Cai J; Yao X; Liu L; Huang J; He J; Xie C; Wu Q; Cao Y; Leung EL
Curr Opin Pharmacol; 2020 Oct; 54():1-10. PubMed ID: 32619934
[TBL] [Abstract][Full Text] [Related]
31. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
32. Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non-small cell lung cancer.
Xin Y; Liu CG; Zang D; Chen J
Front Immunol; 2024; 15():1343450. PubMed ID: 38361936
[TBL] [Abstract][Full Text] [Related]
33. The Challenge of ICIs Resistance in Solid Tumours: Could Microbiota and Its Diversity Be Our Secret Weapon?
Roberto M; Carconi C; Cerreti M; Schipilliti FM; Botticelli A; Mazzuca F; Marchetti P
Front Immunol; 2021; 12():704942. PubMed ID: 34489956
[TBL] [Abstract][Full Text] [Related]
34. The Role of the Gut Microbiome in Cancer Immunotherapy: Current Knowledge and Future Directions.
Kiousi DE; Kouroutzidou AZ; Neanidis K; Karavanis E; Matthaios D; Pappa A; Galanis A
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046762
[TBL] [Abstract][Full Text] [Related]
35. Targeted modulation of gut and intra-tumor microbiota to improve the quality of immune checkpoint inhibitor responses.
Wang W; Fan J; Zhang C; Huang Y; Chen Y; Fu S; Wu J
Microbiol Res; 2024 May; 282():127668. PubMed ID: 38430889
[TBL] [Abstract][Full Text] [Related]
36. Gut microbiota: A double-edged sword in immune checkpoint blockade immunotherapy against tumors.
Wang J; Zhu N; Su X; Yang R
Cancer Lett; 2024 Feb; 582():216582. PubMed ID: 38065401
[TBL] [Abstract][Full Text] [Related]
37. Gut microbiome modulates efficacy of immune checkpoint inhibitors.
Yi M; Yu S; Qin S; Liu Q; Xu H; Zhao W; Chu Q; Wu K
J Hematol Oncol; 2018 Mar; 11(1):47. PubMed ID: 29580257
[TBL] [Abstract][Full Text] [Related]
38. Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome.
Temraz S; Nassar F; Kreidieh F; Mukherji D; Shamseddine A; Nasr R
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360566
[TBL] [Abstract][Full Text] [Related]
39. Gut microbiota: impacts on gastrointestinal cancer immunotherapy.
Lau HCH; Sung JJ; Yu J
Gut Microbes; 2021; 13(1):1-21. PubMed ID: 33435800
[TBL] [Abstract][Full Text] [Related]
40. The impact of microbiota on PD-1/PD-L1 inhibitor therapy outcomes: A focus on solid tumors.
Najafi S; Majidpoor J; Mortezaee K
Life Sci; 2022 Dec; 310():121138. PubMed ID: 36309224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
